Biologics drugs, including monoclonal antibodies, are revolutionizing the treatment of human diseases.
Biologics drugs, including monoclonal antibodies, are revolutionizing the treatment of human diseases. There are more than 60 antibodies that have been approved and over 300 biologic drugs at various stages of drug development. With transformational changes and the success of bioligics, there are increasingly newer challenges in development of biosimilars/bio-betters, immunomodulatory and antibody-drug conjugates (ADCs) biologics.
In this free and educational webinar, you'll learn about:
Rakesh DIXIT, Ph.D., DABT
Vice President R&D | Global Head,